A Study to Assess Relatlimab and Nivolumab Fixed-dose Combination in Chinese Participants With Advanced Solid Tumors

Bristol-Myers Squibb24 enrolled

Overview

The purpose of this study is to assess the safety, drug levels, immunogenicity and preliminary efficacy of BMS-986213 (nivolumab-relatlimab fixed-dose combination) in Chinese participants with advanced solid tumors.

Study Type

INTERVENTIONAL

Allocation

NON_RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Advanced Solid Tumors

Interventions

BMS-986213DRUG

Specified dose on specified days

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Presence of at least one lesion with measurable disease as defined by RECIST v1.1 criteria for response assessment * Participants must have received, and then progressed, or been intolerant to at least one standard treatment regimen in the advanced or metastatic setting, if such a therapy exists * ECOG status of 0 or 1 * Life expectancy of ≥ 12 weeks at the time of informed consent per Investigator assessment Exclusion Criteria: * Participants with history of severe and/or life-threatening toxicity related to prior immune therapy (eg, anti-CTLA-4 or anti-PD-1/PD-L1 treatment or any other antibody or drug specifically targeting T-cell co-stimulation or immune checkpoint pathways) * Participants with an active, known or suspected autoimmune disease * Participants with primary CNS tumors Other protocol-defined inclusion/exclusion criteria apply

Locations (2)

Local Institution - 0001

Beijing, Beijing Municipality, China

Local Institution - 0002

Fuzhou, Fujian, China